
Soleno Therapeutics Investor Relations Material
Latest events

AGM 2025
Soleno Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Soleno Therapeutics Inc
Access all reports
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of rare diseases. The company's primary focus is on Prader-Willi Syndrome (PWS), a genetic disorder characterized by chronic hunger, behavioral problems, and other severe health issues. Soleno's lead product candidate, Diazoxide Choline Extended-Release (DCCR) tablets, is currently undergoing evaluation in a Phase III clinical trial as a potential treatment for PWS. This once-daily oral medication aims to address the disorder's hallmark symptoms and improve patient outcomes. The company is headquartered in Redwood City, California, and its shares are listed on NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SLNO
Country
🇺🇸 United States